Bivalirudin (previously known as Hirulog), derived from the saliva of the leech Hirudo medicinalis, is a small peptide of 20 amino acids with a molecular weight of 2180 Da that reversibly inhibits thrombin activity by incorporating a binding affinity for both the catalytic active site and the anion binding exosite of thrombin.
Beginning in the early 1990s, bivalirudin was used during coronary angioplasty and subsequently underwent further investigation to establish the drug's efficacy. With increasing amounts of clinical data available, bivalirudin has received higher levels of recommendation regarding its use, as reflected in the Class I level of evidence B recommendation for its use in the current American College of Cardiology guidelines for patients presenting across the spectrum of acute coronary syndrome (ACS). 6) Bivalirudin (The Medicines Company, U.S.A.) was approved by FDA in 2000 under the brand name Angiomax and by Committee for Medicinal Products for Human Use (CHMP) in 2004 under the name Angiox; however, the drug has not been marketed in China until now. In contrast with the comprehensive research on the pharmacokinetic features and pharmacological activities of this drug in Europe and North America, studies dealing with the characteristics of bivalirudin in Chinese adults have rarely been reported. To date, only one article 7) focusing on an analytical method for the determination of bivalirudin concentration has been published, offering little information about the pharmacokinetics of bivalirudin in Chinese subjects (the study involved only 9 healthy volunteers aged 20-28 and only one bivalirudin dosage level).
With the great economic growth and aging population in China during the recent decades, the morbidity and mortality of ACS has increased greatly, and percutaneous coronary intervention (PCI) treatment has also become increasingly popular. Thus, comprehensive research concerning the PK and PD of the novel anticoagulant bivalirudin in Chinese subjects should be conducted to aid doctors in using bivalirudin properly in Chinese patients. The aim of this study was to investigate the safety, tolerability, PK and PD of bivalirudin in healthy Chinese subjects.
MATERIALS AND METHODS
The study was conducted in accordance with the Declaration of Helsinki [World Medical Association], Good Clinical Practice (GCP) guidelines and the laws and regulations of the People's Republic of China. The study protocol and informed consent forms were approved by the Independent Ethics Committee and the Institutional Review Board of Peking University First Hospital and the State Food and Drug Administration (SFDA) of China under SFDA approval number 2009L10830. Prior to the beginning of the study, all subjects provided written informed consent.
Volunteers Healthy male or female Chinese subjects aged 18-45 years, with a body mass index (BMI) of 19-25 kg/m 2 , were enrolled. As bivalirudin is partially eliminated via renal excretion, the renal function of subjects was evaluated. Only those with normal renal function (glomerular filtration rate, GFRϾ90 ml/min) could be enrolled in the study. Female subjects were not pregnant and did not have childbearing potential (i.e., either postmenopausal or using medically accepted methods of contraception). Subjects having (or with first-degree relatives having) any known coagulation disorder were excluded, as were those with conditions indicating increased bleeding risk (e.g., melena, acute gastritis and peptic ulcer, a history of menorrhagia, or a prolonged coagulation value on examination). Other exclusion criteria included known hypersensitivity to the study drug and evidence-indicated drug abuse. Study Design and Drug Administration This was a randomized, single-blind, placebo-controlled, parallel-group, dose-escalation study conducted at a single site. Subjects received bivalirudin doses of 0.5 mg/kg, 0.75 mg/kg, 1.05 mg/kg intravenous bolus, or 0.75 mg/kg intravenous bolus followed by an infusion of 1.75 mg/kg per hour for 4 h. Subjects were randomly assigned following simple randomization procedures (computerized random numbers) to bivalirudin or placebo treatment group. The allocation sequence was concealed from the researcher enrolling and assessing subjects in sequentially numbered, opaque, sealed and stapled envelopes. Randomization was carried out by a statistician with no clinical involvement in the trial. Nine subjects were randomized to receive bivalirudin, and three were randomized to receive placebos at each dose level. The sample size was established according to GCP guidelines of SFDA, which recommend 8-12 subjects in each dose group for clinical pharmacokinetic trials.
The study took place at the phase I unit of Peking University First Hospital in Beijing from June 2010 to September 2010.
Subjects were admitted to the study unit the evening before drug administration. Single doses of bivalirudin (Shenzhen Main Luck Pharmaceuticals Inc., Shenzhen, China, batch number: 100401) or placebo were injected intravenously as a bolus or intravenously injected as a bolus followed by infusion the next morning, 1h after a standardized meal. Single-dose vials containing 250 mg of lyophilized bivalirudin powder for injection were each reconstituted with 5 ml of sterile water to yield an initial nominal bivalirudin concentration of 50 mg/ml. These solutions were each injected into an infusion bag containing 45 ml of 0.9% sodium chloride injection to achieve a final nominal bivalirudin concentration of 5 mg/ml. The placebo was a 0.9% sodium chloride injection. Bivalirudin solution and sodium chloride injection look identical in appearance. Subjects were discharged 24 h after drug administration and were requested to return to the study unit 4 d after drug administration for a follow-up visit. Bivalirudin concentration and data analysts were aware of the allocated arm, whereas subjects and laboratory analysts responsible for activated clotting time (ACT), activated partial thromboplastin time (APTT) and prothrombin time (PT) determination were kept blinded to the allocation.
Safety and Tolerability Assessments Safety and tolerability were assessed subjectively and objectively. Subjective tolerability was assessed by questioning subjects about any adverse events (AE). Objective tolerability was assessed at scheduled intervals by physical examination, safety laboratory tests, vital sign measurements (blood pressure and pulse rate, body temperature), 12-lead electrocardiogram (ECG) recordings and fecal occult blood testing (FOBT) (if excrement was obtained). AE information was collected throughout the study, and the severity was classified according to the Medical Dictionary for Regular Activities criteria.
Sample Collection For the PK analysis, 5 ml blood samples were collected into tubes containing ammonium heparinate and centrifuged immediately to obtain plasma samples. These samples were then transferred to polypropylene vials and kept frozen below Ϫ20°C until analysis. For the 0.5 mg/kg, 0.75 mg/kg, 1.05 mg/kg intravenous bolus injection dose groups, samples were collected at dosing (time 0) and at 5, 10, 20, 30, 45, 60, 80, 100 and 120 min after dosing. For the group receiving a 0.75 mg/kg intravenous bolus followed by an infusion of 1.75 mg/kg per hour for 4 h, samples were collected at dosing (time 0) and at 10, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min after bolus injection.
Pharmacodynamic analyses included the determination of ACT, PT and APTT. For the ACT measurement, 3 ml blood samples were collected into a cuvette containing a number of dried reagents (including phospholipid, silica, kaolin, stabilizers, and buffers), and the determination was performed immediately. For the 0.5 mg/kg, 0.75 mg/kg, and 1.05 mg/kg intravenous bolus injection dose groups, samples were collected at dosing (time 0) and at 5, 10, 20, 30, 45, 60, 80, 100, 120 min, 24 h and 72 h after dosing. For the group receiving a 0.75 mg/kg intravenous bolus followed by an infusion of 1.75 mg/kg per hour for 4 h, samples were collected at dosing (time 0) and at 60, 120, 180, 240, 300, 360, 480 min, 24 h and 72 h after bolus injection. For APTT and PT measurement, 3.6 ml blood samples were collected into tubes containing sodium citrate. For the 0.5 mg/kg, 0.75 mg/kg, 1.05 mg/kg intravenous bolus injection dose groups, samples were collected at dosing (time 0) and at 20, 45, 60, 120 min, 24 h and 72 h after dosing. For the group receiving a 0.75 mg/kg intravenous bolus followed by an infusion of 1.75 mg/kg per hour for 4 h, samples were collected at dosing (time 0) and at 120, 240, 360, 480 min, 24 h and 72 h after bolus injection. These samples were also centrifuged immediately to obtain plasma samples, which were transferred to polypropylene vials and immediately submitted to analysis.
Analytical Assays Bivalirudin concentrations were determined using a fully validated liquid-chromatographytandem mass spectrometry (LC/MS/MS) method. Sample Preparation Plasma samples (100 ml) were mixed with 100 ml of an internal standard (Diphenhydramine, purchased from the National Institutes for Food and Drug Control, Beijing, China; batch number: 10006-199705) working solution. The samples were extracted with methanolwater 600 ml (550 ml methanol and 50 ml water) by vortexmixing for 1 min at high speed and centrifuged at 12000ϫg for 10 min, and 20 ml supernatant was introduced into the LC/MS/MS system for analysis.
Instrumentation and Conditions The LC-MS/MS system consisted of an Agilent 1100 series HPLC (Agilent Technologies, Palo Alto, CA, U.S.A.) coupled to an API 4000 mass spectrometer (Applied Biosystems/MDS Sciex, Toronto, Canada). The separation was performed on a Zorbax 300SB-C 18 column (150 mmϫ4.6 mm i.d., 5 mm) (Agilent, Wilmington, DE, U.S.A.) using a mobile phase of methanol-water-formic acid (55 : 44.55 : 0.45, v/v/v) at a flow rate of 0.8 ml/min. The column effluent was split so that approximately 0.4 ml/min entered the mass spectrometer, which was equipped with a TurboIon Spray ionization (ESI) source and operated in positive multiple reaction monitoring (MRM) mode. The source temperature was set at 450°C. The ion spray voltage was 5200 V. Nitrogen was used as the nebulizer gas, curtain gas and collision gas at 40, 15 and 50 psi, respectively. The declustering potential (DP) was set at 63 and 55 V and the collision energy (CE) at 57 and 15 V for bivalirudin and IS, respectively. Singly charged precursor-product ion transitions were monitored at m/z 1091.0→ 650.4 (bivalirudin) and m/z 256.3→167.1 (IS). The dwell time was 150 ms. The Q1 and Q3 resolutions were unit. Peak areas for all components were automatically integrated using Analyst 1.3 software (Applied Biosystems/MDS Sciex, Toronto, Canada).
Method Validation The method was validated with respect to specificity, matrix effect, linearity, recovery, accuracy, precision and stability. The lower and upper limits of quantification for the assay were 15.0 ng/ml and 10000.0 ng/ml, respectively. Samples above the limit of quantification were diluted and reanalyzed to yield results within the calibrated range. The intraday and interday relative standard deviations (a measure of precision) ranged from 6.05 to 6.27% and 2.80 to 9.35%, respectively. The relative error (a measure of accuracy) ranged from Ϫ1.50 to 0.06%.
Pharmacokinetic Parameters The PK parameters assessed included area under the plasma concentration-time curve (AUC 0-tn , AUC 0-∞ ), maximum plasma concentration (C max ), terminal half-life (t 1/2 ), clearance (CL), apparent volume of distribution during the terminal phase (V z ), and mean residence time (MRT). The PK parameters for bivalirudin were derived in WinNonlin Professional Version 6.0 (Phoenix) (Pharsight Corporation, Mountain View, CA, U.S.A.) using noncompartmental methods.
Pharmacodynamic Parameters ACT measurements were performed using the Hemochron ® Response device (International Technidyne Corp., New Albany, Indiana). PT was assessed using freeze-dried rabbit-brain thromboplastin (Neoplastin Plus ® ; Roche Diagnostics, Mannheim, Germany), and APTT was assessed using a kaolin-activated test (Roche Diagnostics). PT and APTT were measured using a ball coagulometer (Amelung KC 10, Lemgo, Germany) according to the manufacturer's instructions.
Statistical Analyses One-way analysis of variance was used to determine the significance of C max /Dose or AUC/ Dose values among groups in the single-dosing study after dose normalization. A value of pϽ0.05 was considered to be significant. Additionally, the slope values with 95% confidence intervals (CIs) for the C max and AUC linearity, were calculated by log-transformed the dose, C max and AUC values, then performing unary regression analysis. To investigate the relationship between PK and PD, scatter-plot and correlation analyses were performed using WinNonlin Professional Version 6.0 (Phoenix).
RESULTS

Demographic Characteristics
Participants were recruited from June 2010 to September 2010. A total of 48 subjects (24 males and 24 females) were enrolled in the study. All subjects were randomly assigned, received intended treatment. There were no losses to follow up or exclusions. There were no early discontinuations during the study, and because there were no protocol violations, all subjects were included in the safety, PK and PD analyses. Baseline demographics for the subjects are shown in Table 1 . The treatment groups were balanced with respect to age and BMI. There were minor between-group differences in gender.
Safety and Tolerability There were no serious adverse events reported during the study. Two treatment-emergent adverse events were reported by two of the 48 subjects. One (increased UREA level: 5.88 mmol/l at screening period and 7.99 mmol/l 24 h after bivalirudin injection; reference range: 1.8-7.1 mmol/l) was reported in the 1.05 mg/kg intravenous bolus group; the other (increased neutrophils absolute (NE#) and neutrophils relative (NE%): 1.97ϫ10 9 /l and 47.8% at screening period and 8.15ϫ10
9 /l and 88.3% 24 h after bivalirudin bolus; reference ranges: NE# 2.0ϫ10 9 /l-7.0ϫ10 9 /l and NE% 50-70%) was reported in the group receiving a 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h. The increased UREA level was considered unlikely to be related to bivalirudin, whereas the increased NE# and NE% were probably related to bivalirudin. Both adverse events were mild in intensity and resolved without treatment. No changes in vital signs or ECG parameters, including the QTc interval, were observed. No bleeding complications occurred with any bivalirudin dosage.
Pharmacokinetics The pharmacokinetic parameters are listed in Table 2 , and the mean plasma bivalirudin concentration-time-profiles for each dosing regimen are displayed in values (95% CIs) for the C max and AUC were 0.87 (0.51, 1.22) and 0.83 (0.60, 1.05), respectively. In group receiving a 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h, bivalirudin concentrations remained at 5000-5500 mg/l within the 4 h infusion period. The mean apparent distribution volume and total clearance remained consistent across the four dosage levels. In all groups, there was no effect of gender on bivalirudin concentration (data not shown).
Pharmacodynamics Bivalirudin prolonged ACT dose dependently within the dose range of 0.5-1.05 mg/kg (Table  3a) . The maximum effect occurred 5 min after dosing, reaching 253 s, 264 s and 305 s for the 0.5, 0.75 and 1.05 mg/kg bolus dose groups, respectively. ACT returned to baseline approximately 2 h after bolus injection in all groups. Placebos had no effect on ACT. In the group receiving a 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h dose, ACT reached peak value (279 s) at 5 min after bolus, remained 250-270 s during the 4 h infusion period and returned to baseline within four hours of infusion discontinuation (8 h after bolus) (Table 3b) . Placebos had no effect on ACT within 8 h after bolus, although some prolongation occurred at 24 h and 72 h after bolus (baseline, 126 s; 24 h, 131 s; 72 h, 139 s); however, these differences were no statistical or clinical significance. Prolongation of PT and APTT (Tables 4, 5) followed patterns similar to the prolongation of ACT. PT and APTT returned to baseline levels after 24 h with all bivalirudin doses.
Pharmacokinetic and Pharmacodynamic Correlations There were strong correlations between bivalirudin concentration and ACT, PT, and APTT prolongations; see Fig. 2A  (rϭ0.97), Fig. 2B (rϭ0.987) and Fig. 2C, (rϭ0.956) , respectively. The PD parameters ACT, PT and APTT mirror the bivalirudin plasma concentrations well.
DISCUSSION
This is the first comprehensive evaluation of the safety, tolerability, pharmacokinetic and pharmacodynamic properties of bivalirudin in healthy Chinese subjects. Bivalirudin was well tolerated in the study, with a low number of drugrelated, treatment-emergent adverse events being reported. There was no evidence of a dose-related increase in adverse events with bivalirudin, and no signs or symptoms of bleeding were reported.
Bivalirudin exhibited linear pharmacokinetics when ad- Peak bivalirudin plasma concentrations were directly correlated to doses ranging from 0.5-1.05 mg/kg. In the dosage group receiving a 0.75 mg/kg intravenous bolus injection, the main PK parameters were consistent with the only previously reported data for bivalirudin in Chinese subjects. 7) In all four investigated dosage groups in this study, the PK properties of bivalirudin observed in the healthy Chinese subjects of this study were similar to those reported in Caucasian subjects. [8] [9] [10] This result may be due to the pharmacokinetic characteristics of bivalirudin, which are associated with a low potential for ethnic sensitivity. Bivalirudin was eliminated via the dual pathways of proteolysis and renal excretion, avoiding pathways based on cytochrome P450s (CYPs) and drug transporters, which may have genetic polymorphisms. [11] [12] [13] [14] Additionally, bivalirudin was administered intravenously, avoiding metabolism by first-pass organs such as the gut and liver that may exhibit potentially polymorphic effects. 15, 16) Bivalirudin also exhibited a linear dose-response anticoagulant effect. The ACT, PT and APTT all increased linearly with an increase in bivalirudin dose. The effects of bivalirudin on the prolongation of ACT, PT and APTT were predictable and closely mirrored the pharmacokinetic time course; close correlation between ACT, PT and APTT prolongations and bivalirudin plasma concentrations was shown in the study. The mechanism of the close correlation between PK and PD can be explained with the anticoagulant mechanism of bivalirudin. Bivalirudin is a direct thrombin inhibitor, it inhibits thrombin by binding with high affinity to a terminal 12-amino acid sequence of thrombin, thus prolong the ACT, PT and APTT. The higher bivalirudin concentration is, the more thrombin is inhibited, and leads to longer ACT, PT and APTT values. According to Fig. 2A , when bivalirudin concentrations are high than 5000 mg/l, the ACT value will longer than 250 s, which is an index to confirm that desired anticoagulant effect during PCI procedure has achieved. Bivalirudin showed an immediate onset of action, and the desired anticoagulant effect (ACTϾ250 s) was rapidly achieved and maintained over the entire infusion period. In addition, because the half life of bivalirudin is very short (only about 0.5 h), its binding with thrombin is reversible. When bivalirudin infusion was stopped, its anticoagulant effects were rapidly reversed, with coagulation times approaching baseline within 4 h after the end of infusion, which ensures its safety.
This study has clearly demonstrated that bivalirudin is well tolerated in healthy Chinese subjects, showing predictable, dose-proportional PK and dose-dependent anticoagulant activity. Furthermore, the tolerability, PK and PD of bivalirudin were very similar in Chinese and Caucasian subjects, [17] [18] [19] suggesting that the metabolism and activity of bivalirudin are not significantly affected by ethnicity.
Bivalirudin has found increasing use as an anticoagulant in cardiovascular and surgical procedures because of its predictable pharmacokinetics and efficacy. 20, 21) However, it has not previously been marketed in China and is currently in advanced development there, with several ongoing clinical trials as of this writing. The possible effects of ethnicity on the efficacy and safety of bivalirudin will be assessed more systematically in future work; however, the findings presented here suggest that there are unlikely to be any clinically relevant differences among different ethnic groups. Ongoing and future studies in large populations may add further evidence that bivalirudin may be administered in the same dosage regimen to Chinese and Caucasian patients.
